Sabin President Peter Hotez Testifies at House Hearings on Zika, Infectious Diseases

Peter Hotez, M.D., Ph.D., president of Sabin, testified this week at two congressional hearings: the House Energy and Commerce Subcommittee on Oversight and Investigations hearing, “Examining the U.S. Public Health Response to the Zika Virus”; and the House Foreign Affairs Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations on “The Growing Threat of Cholera and Other Diseases in the Middle East.”

Statement on the World Health Organization’s Declaration of a Public Health Emergency International Concern for Zika Virus

WASHINGTON, D.C. — Feb. 8, 2016 — On Monday, the World Health Organization (WHO) Director-General, Dr. Margaret Chan, declared Zika a Public Health Emergency International Concern (PHEIC), because of growing concerns of the suspected association between Zika and the rise in detected cases of congenital malformations and neurological complications in newborn babies.

Kenneth Kelley and Jordan Orange Join Sabin Vaccine Institute Board of Trustees

WASHINGTON, D.C. — January 13, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the election of Kenneth Kelley, M.B.A., and Jordan Orange, M.D., Ph.D., to its Board of Trustees. Mr. Kelley is a Harvard Senior Advanced Leadership Fellow, focusing on global health, biosecurity and the market inefficiency leading to a lack of vaccines against neglected tropical diseases (NTDs) and emerging pandemic threats. Dr. Orange is chief of Immunology, Allergy and Rheumatology, and professor and section head for Immunology, Allergy and Rheumatology in the pediatrics department at Baylor College of Medicine.

Axel Hoos, Peter Thoren Appointed Chairman, Vice Chairman of Sabin Board of Trustees

WASHINGTON, D.C. — January 5, 2016 — The Sabin Vaccine Institute (Sabin) is pleased to announce the Board of Trustees unanimously appointed Axel Hoos, M.D., Ph.D., to serve as chairman of the board, and Peter L. Thoren to serve as vice chairman. Both were appointed to interim positions in December 2014.

Statement by the Dengue Vaccine Initiative on the Philippines Regulatory Approval of Sanofi Pasteur’s Dengue Vaccine, Dengvaxia®

December 22, 2015 — The Philippines yesterday became the first Asian country to approve Sanofi Pasteur’s dengue vaccine, Dengvaxia®, marking the second time in less than one month that a dengue vaccine has been licensed for use in a country.

UK Government Allocates £1 billion to Combat Malaria, Other Infectious Diseases

The Sabin Vaccine Institute (Sabin) and its UK sister organization Sabin Foundation Europe, released the following statement on the UK government’s allocation of £1 billion for malaria and other infectious diseases. This funding will be distributed through the newly-developed Ross Fund, created by the Department for International Development (DFID) in collaboration with the Bill and Melinda Gates Foundation.

Pages